Fosamax and Osteonecrosis of the Jaw: Understanding the Link and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: General Health and Science Communication

For decades, general health and science communication has served as the foundational layer for public understanding of medication risks and bone physiology. This legacy context established a baseline awareness that certain pharmaceuticals, particularly those targeting bone metabolism, carry potential adverse effects beyond their intended therapeutic benefits. Within this broad framework, the association between bisphosphonate therapies like Fosamax and osteonecrosis of the jaw emerged as a significant clinical observation, initially documented in oncology and dental medicine. The transition from this general health perspective to a more focused occupational exposure concern requires careful reframing. While the original discourse centered on patient populations receiving therapeutic doses for osteoporosis or cancer-related bone conditions, the underlying question of exposure pathways now extends into workplace environments. Specifically, individuals who handle, manufacture, or administer these compounds may encounter unique exposure scenarios—through inhalation of powdered formulations, dermal contact during preparation, or repeated handling in production settings. This shift does not imply identical risk profiles between therapeutic and occupational contexts, but rather acknowledges that the same biological plausibility for jaw-related complications warrants consideration in industrial hygiene and safety protocols. The bridge concept thus moves from patient-centered risk communication to occupational health surveillance, recognizing that exposure routes, durations, and concentrations in mass production settings differ fundamentally from clinical administration. This transition maintains the neutral, evidence-informed tone of the original health literacy framework while opening a new domain for preventive assessment.

Bridging to Occupational Exposure Concerns

The transition from general health discourse to occupational exposure concerns is grounded in the same biological plausibility that links Fosamax to osteonecrosis of the jaw. While therapeutic use involves controlled doses, occupational exposure may involve repeated contact with powdered formulations or aerosols during manufacturing, preparation, or administration. Although risk profiles differ, the underlying mechanisms—bisphosphonate accumulation in bone, suppression of osteoclast activity, and impaired bone remodeling—are relevant regardless of exposure route. This bridge concept maintains a neutral, evidence-informed tone while expanding the scope of preventive assessment to include workplace safety protocols. The need for occupational health surveillance is underscored by the fact that bisphosphonates can be absorbed through inhalation or dermal contact, and chronic low-level exposure may pose risks that are not yet fully characterized. Therefore, individuals with documented occupational exposure to Fosamax who develop jaw complications should be evaluated for potential causation, taking into account exposure duration, intensity, and other risk factors.

Fosamax and Osteonecrosis of the Jaw: Clinical Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involves the presence of exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, supported by imaging studies that may reveal bone changes, sequestra, or fistulae. The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for increasing bone mass and reducing fracture risk in osteoporosis, it may also impair the jawbone's ability to remodel and repair microdamage, particularly after invasive dental procedures. Multiscale characterization of jawbone in estrogen-deficient rats treated with bisphosphonates has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research suggests that bisphosphonate treatment alters the mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ involve several factors. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress osteoclast activity. This suppression can lead to reduced bone remodeling, impaired healing of microcracks, and increased susceptibility to infection. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning about osteonecrosis of the jaw. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was not significantly different from placebo, which may complicate risk assessment for individual patients.

Causation Considerations for Affected Individuals

Causation-related considerations for affected patients require careful evaluation of temporal relationship, alternative causes, and risk factors. The timeline between exposure and documented harm can vary widely. Symptoms may appear as early as one day after starting the drug or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which supports a causal relationship in some cases. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of bisphosphonate use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with osteonecrosis of the jaw, a serious condition that can occur spontaneously or after dental procedures. The risk is influenced by duration of exposure, concomitant therapies, and dental health. Warnings in the prescribing information address this risk, but the variability in onset and the low incidence in clinical trials highlight the need for individualized risk-benefit assessment. Patients should be informed of the signs and symptoms of ONJ and advised to maintain good oral hygiene and undergo regular dental check-ups. For those requiring invasive dental procedures, a drug holiday may be considered to reduce risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it linked to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and fails to heal. The link is supported by clinical reports and mechanistic studies showing that bisphosphonates suppress bone remodeling, impair healing, and may reduce blood supply to the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the symptoms and risk factors for Fosamax-related ONJ?

Symptoms include exposed bone in the jaw lasting more than eight weeks, pain, swelling, and infection. Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and long duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation determined for individuals who develop ONJ after Fosamax exposure?

Causation evaluation considers temporal relationship (symptoms can appear from one day to months after starting the drug), alternative causes, and risk factors. Recurrence upon rechallenge supports causation. Discontinuation of bisphosphonates may reduce risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.